.png){kind=icon}
定量和/或系统药理学（QSP / SP）建模
新陈代谢，建模，药理学（安全）
Immunotherapy: CAR T and TCR applications
CAR T和TCR肿瘤应用雇用遗传修饰的T细胞表达嵌合抗原受体（汽车）或工程化T细胞受体（TCR）。这种细胞免疫疗法，也称为收养细胞疗法，靶向肿瘤细胞表面上的特异性抗原。Car-T细胞疗法表明了B细胞谱系的血液恶性肿瘤的功效 - 2017年FDA批准了大型B细胞淋巴瘤的第一个Car-T细胞疗法。Car-T细胞疗法显示对实体瘤的承诺，而TCR工程化T细胞疗法在治疗实体肿瘤方面产生了一些阳性结果。
TCRs rely on the interaction with peptide-major histocompatibility complex (pMHC) to produce a therapeutic response, and CARs do not – they utilize a single-chain fragment variant (scFv) which recognizes specific antigens on the tumor cell surface.
Another approach is harnessing stem cells to create a supply of CAR-T cells, which could fast-track treatment for patients. Both types of immunotherapy are being extensively researched. This includes exploring new targets such as BCMA, CD123, CD33 (for CAR-T cells) and WT-1, L1CAM, HPV-16 (for TCR T-cells). Human xenograft models representative of both solid and hematological malignacies are extensively utilized in the preclinical development, and our preclinical oncology team has run more than 450 cell therapy based studies between 2015 and 2020.
Related Capabilities
About our nonclinical animal research models: We provide the utmost care for our research animals and actively pursue advances in animal welfare. As well as ensuring the highest scientific, ethical and regulatory standards, selection of appropriate animal research models for development research is critical to developing safe and effective treatments, devices and products that protect and save lives. Just as we have ethical committee oversight for human trials, we have ethical committees overseeing all aspects of our global animal care and use programs. All of our core, nonclinical facilities are accredited by AAALAC.了解有关我们对更换，重新塑造和炼制非临床研究模式的承诺。